Erectile dysfunction (ED) is a highly prevalent medical condition that extends

far beyond its physiological manifestations, significantly impacting the

quality of life of both patients and their partners. Recent guidelines and
research have substantially advanced our understanding of its complex
pathophysiology and management . This paper will explore the definition,
pathophysiology, causes, psychosocial impact, and contemporary treatment
strategies for ED, with a particular focus on recent insights from oxidative
stress research and updated clinical guidelines from 2024-2025.

Understanding Erectile Dysfunction: A Contemporary Review of

Pathophysiology, Psychosocial Impact, and Treatment

Abstract

Erectile dysfunction (ED) is a prevalent condition affecting millions of men

worldwide, with its incidence increasing with age. This paper provides a
comprehensive overview of ED, examining its definition, prevalence,
pathophysiology, etiology, psychosocial impact, and current treatment
modalities. Recent research highlights the central role of oxidative stress in
endothelial dysfunction, which underpins many cases of ED. Furthermore,
updated guidelines from the European Association of Urology (2025) and the
Fifth International Consultation for Sexual Medicine (2024) emphasize
personalized treatment approaches and the importance of addressing both
organic and psychological components. The paper concludes that effective
management of ED requires a holistic approach that considers the patient’s
physical health, psychological well-being, and partner dynamics, utilizing a
stepped-care model from lifestyle modifications to advanced therapies.

1. Introduction

Erectile dysfunction (ED) is defined as the persistent inability to attain and/or

maintain a penile erection sufficient for satisfactory sexual performance . It is
a common disorder in adult males that leads to withdrawal from sexual
intimacy, psychosocial problems (including poor self-esteem, depression, and
anxiety), decreased work productivity, and a reduction in quality of life for
both affected men and their partners . The prevalence of ED increases with
age, affecting a significant proportion of men over 50 . While aging is a risk
factor, ED is not an inevitable consequence of growing older and is often
associated with modifiable risk factors such as cardiovascular disease,
diabetes, obesity, and lifestyle choices .

2. Physiology of Erection

A normal erection is a complex neurovascular event that relies on the

intricate coordination of the nervous, vascular, and endocrine systems.
Sexual stimulation triggers the release of nitric oxide (NO) from non-
adrenergic non-cholinergic (NANC) neurons and endothelial cells in the
corpus cavernosum . NO then diffuses into cavernosal smooth muscle cells,
activating the enzyme guanylyl cyclase, which catalyzes the conversion of
guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP).
As a second messenger, cGMP reduces intracellular calcium levels, leading to
smooth muscle relaxation. This relaxation allows the sinusoidal spaces within
the corpora cavernosa to expand and fill with blood, a process further
enhanced by the compression of subtunical venules against the tunica
albuginea, which reduces venous outflow (the corporeal veno-occlusive
mechanism). The result is a sustained rigid erection . The pathway is
terminated by the breakdown of cGMP by phosphodiesterase type 5 (PDE5)
enzymes, which return the cavernosal smooth muscle to a contracted, flaccid
state .

3. Pathophysiology of Erectile Dysfunction

ED can result from disruptions at any point in the complex cascade of events
required for an erection. These disruptions are broadly categorized as
psychogenic, organic, or mixed, with most cases having a significant organic
component .

3.1 The Central Role of Oxidative Stress

3.2
Recent research has identified oxidative stress (OS) as a significant
contributing causative factor in the pathophysiology of ED . Oxidative stress
occurs when there is an imbalance between the production of reactive
oxygen species (ROS) and the body’s antioxidant defenses. Key sources of
ROS include NADPH oxidase, xanthine oxidase, uncoupled endothelial NO
synthase (eNOS), and the mitochondrial electron transport chain .

OS disrupts erectile function through several mechanisms:

· Impaired NO Signaling: ROS, particularly superoxide anions, rapidly

scavenge NO, reducing its bioavailability. This leads to endothelial
dysfunction characterized by reduced vasodilation, increased vascular tone,
and inflammation .

· Endothelial Dysfunction: OS damages the endothelial lining of blood

vessels, impairing its ability to produce NO and respond to vasodilatory
stimuli .

· Neuronal Damage: ROS can cause the death of nitrergic neurons and
reduce the signaling of neuronal NO synthase (nNOS), exacerbating ED .

· Penile Remodeling: In conditions like prostatectomy and diabetes, OS

contributes to penile tissue remodeling, including smooth muscle apoptosis
and increased collagen deposition (fibrosis), which can lead to irreversible ED
.

3.3 Vascular Causes

3.4

Vascular disease is the most common organic cause of ED. Atherosclerosis of

the cavernosal arteries, often secondary to risk factors like smoking,
hypertension, and diabetes, reduces arterial inflow . Endothelial dysfunction,
mediated by reduced NO, limits the arteries’ ability to dilate. Veno-occlusive
dysfunction, or “venous leak,” where the veins fail to compress, prevents the
maintenance of an erection . Importantly, ED is often an early warning sign
of silent cardiovascular disease, as the smaller penile arteries are affected by
atherosclerosis before the larger coronary arteries .
3.3 Neurogenic Causes

Neurological disorders can interrupt the neural signals required for an

erection. Common causes include stroke, multiple sclerosis, peripheral
neuropathy (particularly from diabetes), and spinal cord injuries . Iatrogenic
nerve damage during pelvic surgeries, such as radical prostatectomy for
prostate cancer, is a significant cause of ED, although nerve-sparing
techniques have improved outcomes .

3.5 Hormonal Causes

3.6

Hormonal imbalances, particularly hypogonadism (testosterone deficiency),

can lead to ED. Testosterone is crucial for sexual desire (libido) and supports
the NO pathway. Hypogonadism can be primary (testicular failure) or
secondary (hypothalamic-pituitary axis dysfunction) . Other endocrine
disorders, such as hyperprolactinemia, hyperthyroidism, and hypothyroidism,
can also contribute .

3.5 Other Organic Causes

· Structural Abnormalities: Peyronie’s disease, characterized by fibrous

plaque formation in the tunica albuginea, causes penile curvature and can
make erection painful or difficult .

· Drug-Induced: Numerous medications can cause ED, including

antihypertensives (especially thiazide diuretics and beta-blockers),
antidepressants (SSRIs), and antiandrogens .

· Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): Men with

CP/CPPS are at higher risk for poor sexual functioning, possibly due to pain,
psychological distress, and local inflammation .

3.7 Psychogenic Causes

3.8
Psychological factors are present in nearly all cases of ED but are the primary
cause in a minority. They can be primary (e.g., guilt, fear of intimacy) or,
more commonly, secondary (reactive) to the ED itself, creating a vicious
cycle of performance anxiety and worsening dysfunction . Depression and
stress are major contributors .

Table 1: Common Causes and Features of Erectile Dysfunction

Cause Category Examples Clinical Features

Vascular Arterial blockage, Venous leak Risk factors (HTN, DM), inability to
maintain erection

Neurologic Diabetic neuropathy, MS, Spinal cord injury Known neurologic

disease, possible numbness or weakness

Endocrine Hypogonadism, Thyroid disorders Low libido, mood changes, signs

of hormone imbalance

Structural Peyronie’s disease Penile plaque, curvature during erection, pain

Psychogenic Depression, Performance anxiety Situational ED, good nocturnal

erections, mood symptoms

4. Etiology and Risk Factors

The risk factors for ED largely mirror those for cardiovascular disease,
reinforcing the link between the two conditions .

· Non-Modifiable Risk Factors: Age is the strongest independent risk factor.

The prevalence and severity of ED increase steadily with advancing age .

· Modifiable Risk Factors:

· Cardiometabolic: Diabetes mellitus, hypertension, dyslipidemia, and

obesity are strongly associated with ED .

· Lifestyle: Smoking, excessive alcohol consumption, and physical inactivity

significantly increase risk . A poor-quality diet, particularly one high in
processed foods and low in fruits and vegetables, contributes to ED
pathogenesis .

· Iatrogenic: Pelvic surgery (prostatectomy, cystectomy) and pelvic radiation

are common causes .

5. Psychosocial and Economic Impact

The consequences of ED extend far beyond the physical inability to engage

in intercourse. A pragmatic literature review confirmed that men with ED
have a substantially poorer quality of life than men without ED, with
significantly lower mental and physical component summary scores . The
psychosocial outcomes include diminished sexual confidence, low self-
esteem, and symptoms of depression .

The Impact also extends to the partner. Studies show that female partners
are significantly less satisfied and engage in sexual activity less frequently
after their partner develops ED . This can lead to relationship difficulties and
decreased overall relationship satisfaction .

Furthermore, ED poses a substantial economic burden. Men with ED have

significantly higher rates of absenteeism (up to two times higher) and work
productivity impairment compared to men without ED, underscoring the
broader societal impact of the condition .

6. Diagnosis

The diagnostic approach to ED has been refined in recent guidelines,

emphasizing a patient-centered and stepwise evaluation .

1. Clinical Evaluation: A detailed medical, sexual, and psychosocial history is

paramount. This includes assessing the onset, duration, and severity of
symptoms, and differentiating between situational and global ED. Validated
questionnaires like the International Index of Erectile Function (IIEF) can be
useful . Screening for depression is also recommended .

2. Physical Examination: A focused examination should assess for signs of

hypogonadism (e.g., testicular atrophy), Peyronie’s disease (penile plaque),
and neurological or vascular disease (e.g., reduced peripheral pulses) .

3. Laboratory Testing: Basic testing includes morning serum testosterone

levels (total and free) to screen for hypogonadism . Additional tests for
glucose, lipids, or prolactin may be indicated based on clinical findings .

4. Specialized Testing: In select cases, such as when primary psychogenic ED

is suspected, nocturnal penile tumescence (NPT) testing can help distinguish
psychogenic from organic causes. Penile Doppler ultrasound, performed after
intracavernosal injection of a vasodilator, is used to assess vascular
hemodynamics in men considering invasive interventions or with suspected
vascular injury .

7. Treatment

The goal of ED treatment is to restore satisfactory sexual function, and the

choice of therapy should be a shared decision between the clinician and
patient, considering invasiveness, tolerability, effectiveness, and patient
expectations . The 2025 EAU guidelines support a personalized, stepped-care
approach .

7.1 Lifestyle Modifications and First-Line Interventions

7.2

For all patients, addressing underlying modifiable risk factors is the essential
first step. This includes lifestyle changes such as increased physical activity,
weight loss, smoking cessation, and dietary improvements . For men with
documented hypogonadism, testosterone therapy (TTh) may be
recommended, though it requires appropriate indication and follow-up .

7.3 Oral Pharmacotherapy

7.4
Oral PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) are the
mainstay of first-line pharmacologic therapy due to their efficacy, safety, and
ease of use . They work by enhancing the NO-cGMP pathway, facilitating
smooth muscle relaxation in response to sexual stimulation. While they have
similar efficacy (60-75%), they differ in their onset and duration of action . A
key contraindication is the concurrent use of nitrates, as the combination can
cause severe hypotension .

7.3 Second-Line Therapies

For patients who do not respond to or cannot tolerate oral medications,

second-line options are available.

· Vacuum Erection Devices (VEDs): These devices create negative pressure,

drawing blood into the penis, which is then retained by a constriction ring
placed at the base. They are a non-invasive option with high satisfaction
rates, though some men find them cumbersome .

· Intracavernosal Injections (ICI): Injection of vasoactive agents (e.g.,

alprostadil, papaverine, phentolamine) directly into the corpus cavernosum
produces an erection in most men. While effective, the need for self-injection
can lead to high dropout rates .

· Intraurethral Alprostadil: This involves inserting a small pellet of alprostadil

into the urethra. It is less effective than ICI but may be an option for men
averse to needles .

7.5 Third-Line and Emerging Therapies

7.6

· Penile Prosthesis: For men with refractory ED, surgical implantation of a

semi-rigid or inflatable penile prosthesis offers a definitive and highly
satisfactory solution. Patients with ED and Peyronie’s disease may be offered
penile prosthesis implantation .

· Low-Intensity Shockwave Therapy (Li-SWT): This is an emerging treatment

for mild ED, thought to promote angiogenesis and improve vascularization,
though its long-term efficacy is still being established .
· Future Directions: Research is exploring nanotechnology for targeted drug
delivery and regenerative therapies to promote nerve regeneration and
reverse penile remodeling .

Table 2: Treatment Modalities for Erectile Dysfunction

Treatment Level Modality Examples / Mechanism Key Considerations

First-Line Lifestyle Modification Diet, exercise, smoking cessation Essential

for all patients; addresses root causes

Oral Medications PDE5 inhibitors (sildenafil, tadalafil) Easy to use, effective;

contraindicated with nitrates

Testosterone Therapy For men with hypogonadism Requires appropriate

diagnosis and monitoring

Second-Line Vacuum Devices Mechanical blood draw Non-invasive; some find

it cumbersome

Intracavernosal Injections Alprostadil, papaverine, phentolamine Highly

effective; risk of priapism, patient aversion to needles

Intraurethral Alprostadil Medicated pellet Less effective than injections;

urethral pain possible

Third-Line Penile Prosthesis Semi-rigid or inflatable implants Definitive

solution for refractory cases; irreversible

Emerging Li-SWT Promotes angiogenesis For mild ED; long-term data still
evolving

8. Conclusion

Erectile dysfunction is a common and distressing condition with multifactorial

origins. It is now understood as a complex disorder where organic factors,
particularly vascular health and oxidative stress, frequently intersect with
psychological responses. Recent advances have solidified the role of
endothelial dysfunction and oxidative stress as key pathophysiological
drivers, explaining its strong link to cardiovascular disease. The 2025 EAU
guidelines reinforce the need for a personalized, stepwise approach to
management, beginning with lifestyle modification and progressing through
evidence-based therapies as needed. Recognizing the profound impact of ED
on quality of life, mental health, and partner relationships is crucial .
Ultimately, effective management requires a holistic, patient-centered
strategy that integrates physical and psychological care to improve
outcomes and overall well-being.

References

1. Kaltsas A, Zikopoulos A, Dimitriadis F, et al. Oxidative Stress and Erectile

Dysfunction: Pathophysiology, Impacts, and Potential Treatments. Int J Mol
Sci. 2024;46(8):8807-8834.

2. Salonia A, Bettocchi C, Boeri L, et al. European Association of Urology

Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male
Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s
Disease. Eur Urol. 2025;88(1):76-102.

3. Elterman DS, Bhattacharyya SK, Mafilios M, et al. The quality of life and
economic burden of erectile dysfunction. Res Rep Urol. 2021;13:79-86.

4. Kim NN, et al. Basic science and translational research: recommendations

from the Fifth International Consultation for Sexual Medicine (ICSM 2024).
Sex Med Rev. 2025;13(4):483-512.

5. Roshdy WM, Farag AM, Ghobish AA, El-Sakka AI. Erectile dysfunction
among patients with chronic prostatitis/chronic pelvic pain syndrome. Suez
Canal Univ Med J. 2025;28(7):1-10.

6. Jimbo M. Erectile Dysfunction. MSD Manual Professional Edition. Sep 2024.

7. McCabe MP, et al. A systematic review of the psychosocial outcomes

associated with erectile dysfunction: does the impact of erectile dysfunction
extend beyond a man’s inability to have sex? J Sex Med. 2014;11(2):347-63.

8. Agarwal SK. The Role of Diet in the Pathogenesis of Erectile Dysfunction.

Cardiol Angiol Int J. 2022;11(2):19-30.

9. Common Causes and Features of Erectile Dysfunction. MSD Manual

Consumer Version. Feb 2026.